Shopping Cart
Remove All
Your shopping cart is currently empty
Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) that targets a specific epitope of CD2 subset 1, a cell-surface glycoprotein found on multiple myeloma cells [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $415 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $1,230 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,990 | 2-4 weeks | 2-4 weeks |
| Description | Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) that targets a specific epitope of CD2 subset 1, a cell-surface glycoprotein found on multiple myeloma cells [1]. |
| In vitro | Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) composed of a humanized recombinant immunoglobulin G1κ targeting a unique epitope of CD2 subset 1 (CS1, also known as SLAMF7). It is linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline linker, demonstrating potent cytotoxic activity against CS1-expressing cancer cells [1]. |
| In vivo | Azintuxizumab vedotin (ABBV-838) demonstrated single-agent antitumor activity in a mouse model xenografted with human multiple myeloma [1]. |
| Synonyms | ABBV-838 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Cas No. | 1826819-58-2 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.